The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents
Open accessAbstract
BACKGROUND: New-generation coronary stents that release zotarolimus or everolimus have been shown to reduce the risk of restenosis. However, it is unclear whether there are differences in efficacy and safety between the two types of stents on the basis of prospectively adjudicated end points endorsed by the Food and Drug Administration. METHODS: In this multicenter, noninferiority trial with minimal exclusion criteria, we randomly assigned 2292 patients to undergo treatment with coronary stents releasing either zotarolimus or everolimus. Twenty percent of patients were randomly selected for repeat angiography at 13 months. The primary end point was target-lesion failure, defined as a composite of death from cardiac causes, any myocardial infarction (not clearly attributable to a nontarget vessel), or clinically indicated target-lesion revascularization within 12 months. The secondary angiographic end point was the extent of in-stent stenosis at 13 months. RESULTS: At least one off-label criterion for stent placement was present in 66% of patients. The zotarolimus-eluting stent was noninferior to the everolimus-eluting stent with respect to the primary end point, which occurred in 8.2% and 8.3% of patients, respectively (P<0.001 for noninferiority). There were no significant between-group differences in the rate of death from cardiac causes, any myocardial infarction, or revascularization. The rate of stent thrombosis was 2.3% in the zotarolimus-stent group and 1.5% in the everolimus-stent group (P=0.17). The zotarolimus-eluting stent was also noninferior regarding the degree (+/-SD) of in-stent stenosis (21.65+/-14.42% for zotarolimus vs. 19.76+/-14.64% for everolimus, P=0.04 for noninferiority). In-stent late lumen loss was 0.27+/-0.43 mm in the zotarolimus-stent group versus 0.19+/-0.40 mm in the everolimus-stent group (P=0.08). There were no significant between-group differences in the rate of adverse events. CONCLUSIONS: At 13 months, the new-generation zotarolimus-eluting stent was found to be noninferior to the everolimus-eluting stent in a population of patients who had minimal exclusion criteria. (ClinicalTrials.gov number, NCT00617084.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationFractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention
Tonino, P. A. L., De Bruyne, B., Pijls, N. H. J., Siebert, U., Ikeno, F., van `t Veer, M., Klauss, V., Manoharan, G., Engstrøm, T., Oldroyd, K. G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807611 · Cited by 4,260
Self-citationThe SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.
Sianos, G., Morel, M., Kappetein, A. P., Morice, M., Colombo, A., Dawkins, K. D., van den Brand, M., Dyck, N. V., Russell, M. E., Mohr, F. W., et al. (2005) · PubMed · Cited by 2,293
Self-citationSerruys, P. W., Kutryk, M. J. B., & Ong, A. T. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmra051091 · Cited by 762
Self-citationKedhi, E., Joesoef, K. S., McFadden, E., Wassing, J., van Mieghem, C., Goedhart, D., & Smits, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62127-9 · Cited by 687
Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization
Windecker, S., Remondino, A., Eberli, F. R., Jüni, P., Räber, L., Wenaweser, P., Togni, M., Billinger, M., Tüller, D., Seiler, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051175 · Cited by 593
Self-citationStone, G. W. (2008) · JAMA · doi:10.1001/jama.299.16.1903 · Cited by 582
Garg, S., & Serruys, P. W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.007 · Cited by 501
Self-citationCook, S., Ladich, E., Nakazawa, G., Eshtehardi, P., Neidhart, M., Vogel, R., Togni, M., Wenaweser, P., Billinger, M., Seiler, C., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.854398 · Cited by 480
Self-citationWiviott, S. D., Braunwald, E., McCabe, C. H., Horvath, I., Keltai, M., Herrman, J.-P. R., Van de Werf, F., Downey, W. E., Scirica, B. M., Murphy, S. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60422-5 · Cited by 453
Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction
Stone, G. W., Lansky, A. J., Pocock, S. J., Gersh, B. J., Dangas, G., Wong, S. C., Witzenbichler, B., Guagliumi, G., Peruga, J. Z., Brodie, B. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810116 · Cited by 443
Serruys, P. W. J. C., Ruygrok, P., Neuzner, J., Piek, J. J., Seth, A., Schofer, J. J., Richardt, G., Wiemer, M., Carrié, D., Thuesen, L., et al. (2006) · PubMed · Cited by 346
Self-citationStent Thrombosis Redux — The FDA Perspective
Farb, A., & Boam, A. B. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068304 · Cited by 284
Vranckx, P., Cutlip, D. E., Mehran, R., Kint, P.-P., Silber, S., Windecker, S., & Serruys, P. W. J. C. (2010) · EuroIntervention · doi:10.4244/eijv5i7a146 · Cited by 281
Self-citationImpact of polymer hydrophilicity on biocompatibility: Implication for DES polymer design
Hezi‐Yamit, A., Sullivan, C., Wong, J., David, L., Chen, M., Cheng, P., Shumaker, D., Wilcox, J. N., & Udipi, K. (2009) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32057 · Cited by 165
Claessen, B. E. P. M., Beijk, M. A. M., Legrand, V., et al. (2009) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.108.831800.108.831800 · Cited by 124
Udipi, K., Chen, M., Cheng, P., Jiang, K. W., Judd, D., Cáceres, A., Melder, R. J., & Wilcox, J. N. (2007) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31664 · Cited by 68
FDA panel, 7 and 8 December 2006 - The impact on our practice and research.
Serruys, P. W. J. C. (2007) · PubMed · Cited by 16
Self-citation
Cited by
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
Self-citationDeveloped with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), Authors/Task Force Members, Wijns, W., Kolh, P., Danchin, N., Di Mario, C., Falk, V., Folliguet, T., Garg, S., Huber, K., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq277 · Cited by 3,184
Self-citationFractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease
De Bruyne, B., Pijls, N. H. J., Kalesan, B., Barbato, E., Tonino, P. A. L., Piroth, Z., Jagic, N., Möbius-Winkler, S., Rioufol, G., Witt, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205361 · Cited by 2,772
Self-citation
Metadata
- Authors
- Serruys, P. W., Silber, S., Garg, S., van Geuns, R. J., Richardt, G., Buszman, P. E., Kelbæk, H., van Boven, A. J., Hofma, S. H., Linke, A., Klauss, V., Wijns, W., Macaya, C., Garot, P., DiMario, C., Manoharan, G., Kornowski, R., Ischinger, T., Bartorelli, A., Ronden, J., Bressers, M., Gobbens, P., Negoita, M., van Leeuwen, F., & Windecker, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-08
- Volume
- 363
- Issue
- 2
- Pages
- 136-146
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2144552468
- Cited by
- 670
- References
- 18
- FWCI
- 78.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.